<DOC>
	<DOCNO>NCT02727608</DOCNO>
	<brief_summary>This dual centre , single arm , exploratory study possibility use eculizumab ( Soliris ) prevent/reduce destruction islet Langerhans portal infusion islet patient diabetic accept islet transplant .</brief_summary>
	<brief_title>Complement Inhibitor Eculizumab Clinical Islet Transplantation</brief_title>
	<detailed_description>This dual centre , single arm , exploratory study possibility use eculizumab ( Soliris ) prevent/reduce destruction islet Langerhans portal infusion islet patient diabetic accept islet transplant . Ten patient 2 centre ( Uppsala University Hospital Karolinska University Hospital Stockholm ) transplant . The purpose study investigate selective complement inhibition eculizumab combine standard anticoagulation transplantation reduce extent early tissue loss portal infusion islet .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Complement System Proteins</mesh_term>
	<mesh_term>Complement Inactivating Agents</mesh_term>
	<criteria>Patients 18 65 year age Patients able provide write informed consent Absent stimulate cpeptide ( &lt; 0.1 nmol/L ) . This include also previously islettransplanted patient detectable cpeptide . Patients fear severe hypoglycemia Female patient child bear potential must negative pregnancy test ( sÎ²HCG ) must practice effective , reliable medical accept contraceptive regimen eculizumab treatment study end 75 day . Patients vaccinate Neisseria meningitides patient accept adequate antibiotic prophylaxis Body mass index &gt; 30 kg/m2 Untreated proliferative diabetes retinopathy Recipient concomitant organ transplantation Glomerular filtration rate &lt; 50 mL/min first islet transplantation Positive Tcell crossmatching Complement Depending Cytotoxicity ( CDC ) Pregnancy lactate Active ongoing infection , bacterial viral Unresolved meningococcal disease Known bleeding disorder Known complement disorder Have receive investigational drug within 30 day inclusion History drug alcohol abuse within last year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>